- Diquafosol
-
-
2026-08-08
- CAS:59985-21-6
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 500kg
- Diquafosol Sodium
-
-
2025-12-19
- CAS:59985-21-6
- Min. Order: 5kg
- Purity: 98%-102%
- Supply Ability: 200kg
- Diquafosol
-
- $1.10
-
2025-06-25
- CAS:59985-21-6
- Min. Order: 1g
- Purity: 99.0% min
- Supply Ability: 100 tons min
|
| | Diquafosol Basic information |
| Product Name: | Diquafosol | | Synonyms: | [[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-phosphinic acid;Diquafosol;Diquafosol [inn:ban];Diquafosol [inn];Kpy 998;p1,p4-Bis(5'-uridyl) tetrahydrogen tetraphosphate;Unii-7828vc80fj;P1,P4-Diuridine 5'-Tetraphosphate | | CAS: | 59985-21-6 | | MF: | C18H26N4O23P4 | | MW: | 790.31 | | EINECS: | | | Product Categories: | Agonists;Bases & Related Reagents;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals | | Mol File: | 59985-21-6.mol |  |
| | Diquafosol Chemical Properties |
| density | 2.044±0.06 g/cm3(Predicted) | | storage temp. | Store at 0-8 °C | | solubility | Water (Slightly) | | pka | 0.40±0.50(Predicted) | | form | Solid | | color | White to Pale Beige | | Stability: | Hygroscopic | | InChIKey | NMLMACJWHPHKGR-BTTIJRIRNA-N |
| | Diquafosol Usage And Synthesis |
| Uses | Diquafosol is a dinucleoside derivative of uridine that acts as a selective P2Y2 receptor agonist. Diquafosol is used as a therapeutic agent in the treatment of dry eye syndrome. | | Definition | ChEBI: A pyrimidine ribonucleoside 5'-tetraphosphate compound having 5'-uridinyl residues at the P1- and P4-positions. | | in vivo | Diquafosol (ophthalmic solution 3%; eyedrop, four times daily for 28 days) reduces intracellular ROS levels, apoptosis, and inflammation in rat[1]. | Animal Model: | 6 weeks, 160-180 g Wistar female rats (dry eye model)[1] | | Dosage: | ophthalmic solution 3% | | Administration: | eyedrop, four times daily (8, 12 AM; 4, 8 PM) for 28 days | | Result: | Increased the expression of phospho-Erk1/2, phospho-Akt, and phospho-p90RSK, inhibits apoptosis, decreased the IL-1β, TNF-α expression. |
| | IC 50 | P2Y2 Receptor |
| | Diquafosol Preparation Products And Raw materials |
|